Long term treatment of rheumatoid arthritis with rituximab

Research output: Contribution to journalArticle

Abstract

B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.

Original languageEnglish
Pages (from-to)591-594
Number of pages4
JournalAutoimmunity Reviews
Volume8
Issue number7
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Rheumatoid Arthritis
B-Lymphocytes
CD20 Antigens
Retreatment
Surface Antigens
Observational Studies
Monoclonal Antibodies
Clinical Trials
Safety
Therapeutics
Rituximab

Keywords

  • B-lymphocyte
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Long term treatment of rheumatoid arthritis with rituximab. / Caporali, Roberto; Caprioli, Marta; Bobbio-Pallavicini, Francesca; Bugatti, Serena; Montecucco, Carlomaurizio.

In: Autoimmunity Reviews, Vol. 8, No. 7, 06.2009, p. 591-594.

Research output: Contribution to journalArticle

@article{98bd5b9f244c410ea791f43c3b002aa9,
title = "Long term treatment of rheumatoid arthritis with rituximab",
abstract = "B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.",
keywords = "B-lymphocyte, Rheumatoid arthritis, Rituximab",
author = "Roberto Caporali and Marta Caprioli and Francesca Bobbio-Pallavicini and Serena Bugatti and Carlomaurizio Montecucco",
year = "2009",
month = "6",
doi = "10.1016/j.autrev.2009.02.008",
language = "English",
volume = "8",
pages = "591--594",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Long term treatment of rheumatoid arthritis with rituximab

AU - Caporali, Roberto

AU - Caprioli, Marta

AU - Bobbio-Pallavicini, Francesca

AU - Bugatti, Serena

AU - Montecucco, Carlomaurizio

PY - 2009/6

Y1 - 2009/6

N2 - B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.

AB - B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chimeric monoclonal antibody that depletes B-cells by binding to the CD20 surface antigen that has been approved for the treatment of RA. Its efficacy has been clearly demonstrated by different clinical trials and, recently, in long-term observational studies. The use of rituximab in clinical practice has highlighted its efficacy and safety over more than 5 years of treatment, as well as to try to understand the timing for retreatment of patients relapsing after a good initial response.

KW - B-lymphocyte

KW - Rheumatoid arthritis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=67349120767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349120767&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.02.008

DO - 10.1016/j.autrev.2009.02.008

M3 - Article

C2 - 19393205

AN - SCOPUS:67349120767

VL - 8

SP - 591

EP - 594

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -